1 - 25 of 5
| Creator | Title | Description | Subject | Date | ||
|---|---|---|---|---|---|---|
| 1 |
 |
Young, Michael | The Contributions of Elastin to Ligament Viscoelasticty | Ligaments exhibit viscoelastic behavior in response to strain. This behavior protects joints from injury during loading. Collagen is the primary structural component of ligaments, but does not account fully for the viscoelastic behavior. Elastin is another structural protein in ligaments, and provid... | 2017 | |
| 2 |
 |
Schlegel, Isabelle B. | Peptide-fab conjugates to improve treatment of neovascular age-related macular degeneration | Age-Related Macular Degeneration (AMD), a chronic disease of the eye and leading cause of blindness in Americans over 50, is often treated with agents that inhibit Vascular Endothelial Growth Factor (VEGF). Ranibizumab is an anti-VEGF antibody fragment (Fab) effective at treating over 90% of AMD pat... | 2021 | |
| 3 |
 |
Grimmett, Rollin | Effects of Hypoxia and High Fat Diet on D. Melanogaster Heart Physiology | Heart disease severely affects millions of people worldwide, and is caused by various environmental and genetic factors. The aim of this study is to examine the combined physiological effects of hypoxia and a high fat diet (two known causes) on Drosophila Melanogaster heart structure. Sets of adult ... | 2017 | |
| 4 |
 |
Adams, Samuel I. | Correcting acoustic phase aberrations in focused ultrasound treatments for breast cancer | Breast cancer is the most diagnosed cancer worldwide. Early-stage localized cancers are currently treated with surgical lumpectomy and radiation. Focused ultrasound is a disruptive technology that can replace conventional surgical and radiation therapies to provide noninvasive cancer treatment. This... | 2021 | |
| 5 |
 |
Armstrong, Blair P. | Lower critical solution temperature behavior of elastin-coiled-coil polymer, a potential platform for treatment of non-hodgkin's lymphoma | Non-Hodgkin's lymphoma takes the lives of 20,000 Americans each year. When traditional therapies fail, clinicians have turned to a drug, rituximab, for treatment. However, rituximab is now curative for less than 50% of patients and new treatments are needed. Drug-free macromolecular therapeutics (DF... | 2021 |
1 - 25 of 5